Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of April 2021. The document serves as a transaction notification regarding a specific corporate action involving the company's Performance Share Plan.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It reports a single transaction event:
- Transaction Type: Acquisition of Ordinary Shares via dividend re-investment.
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Volume: 10,892.850 shares.
- Price: £13.2160 per share.
- Date: April 12, 2021.
- Exchange: London Stock Exchange (XLON).
Material Changes
The filing details an acquisition of shares by Ms. E Walmsley, Chief Executive Officer, following the re-investment of dividends paid on April 8, 2021. These shares are subject to a 2-year holding period under the Company's Performance Share Plan. No other material changes to the company's financial position or operations are disclosed in this specific document.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the mandatory disclosure of the executive share transaction.
Key Facts for Investor Verification
- Verify the total number of shares held by the CEO post-transaction in subsequent filings.
- Confirm the dividend payment date of April 8, 2021, and the re-investment mechanism details in the company's annual report.
- Note that this filing is a regulatory disclosure of an insider transaction and does not reflect the company's overall quarterly or annual financial performance.